These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 36425742)

  • 1. The Facts and Fiction of Olanzapine-Samidorphan Fixed Dose Combination.
    Das N; Faheem A; Shoib S
    Alpha Psychiatry; 2022 Jul; 23(4):210-211. PubMed ID: 36425742
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetics and Short-term Safety of ALKS 3831, a Fixed-dose Combination of Olanzapine and Samidorphan, in Adult Subjects with Schizophrenia.
    Sun L; McDonnell D; von Moltke L
    Clin Ther; 2018 Nov; 40(11):1845-1854.e2. PubMed ID: 30348514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: Results from a phase 1 QT/QTc study.
    Sun L; Yagoda S; Xue H; Brown R; Nangia N; McDonnell D; Rege B; von Moltke L; Darpo B
    Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jun; 100():109881. PubMed ID: 32004636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase I Open-Label Study to Evaluate the Effects of Rifampin on the Pharmacokinetics of Olanzapine and Samidorphan Administered in Combination in Healthy Human Subjects.
    Sun L; McDonnell D; Yu M; Kumar V; von Moltke L
    Clin Drug Investig; 2019 May; 39(5):477-484. PubMed ID: 30888624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study.
    Correll CU; Newcomer JW; Silverman B; DiPetrillo L; Graham C; Jiang Y; Du Y; Simmons A; Hopkinson C; McDonnell D; Kahn RS
    Am J Psychiatry; 2020 Dec; 177(12):1168-1178. PubMed ID: 32791894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of Physiologically Based Pharmacokinetic Modeling to Predict the Effect of Renal Impairment on the Pharmacokinetics of Olanzapine and Samidorphan Given in Combination.
    Sun L; von Moltke L; Rowland Yeo K
    Clin Pharmacokinet; 2021 May; 60(5):637-647. PubMed ID: 33313995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olanzapine/Samidorphan: A New Combination Treatment for Schizophrenia and Bipolar I Disorder Intended to Reduce Weight Gain.
    Corrao MM; Nelson LA
    CNS Drugs; 2022 Jun; 36(6):605-616. PubMed ID: 35644903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population Pharmacokinetics of Olanzapine and Samidorphan When Administered in Combination in Healthy Subjects and Patients With Schizophrenia.
    Sun L; Mills R; Sadler BM; Rege B
    J Clin Pharmacol; 2021 Nov; 61(11):1430-1441. PubMed ID: 34018607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using physiologically-based pharmacokinetic modeling for predicting the effects of hepatic impairment on the pharmacokinetics of olanzapine and samidorphan given as a combination tablet.
    Sun L; Barter Z; von Moltke L; Rowland Yeo K
    CPT Pharmacometrics Syst Pharmacol; 2021 Sep; 10(9):1071-1080. PubMed ID: 34185436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia.
    Martin WF; Correll CU; Weiden PJ; Jiang Y; Pathak S; DiPetrillo L; Silverman BL; Ehrich EW
    Am J Psychiatry; 2019 Jun; 176(6):457-467. PubMed ID: 30845818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olanzapine/Samidorphan: New Drug Approved for Treating Bipolar I Disorder and Schizophrenia.
    Monahan C; McCoy L; Powell J; Gums JG
    Ann Pharmacother; 2022 Sep; 56(9):1049-1057. PubMed ID: 35040357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A meta-analysis comparing short-term weight and cardiometabolic changes between olanzapine/samidorphan and olanzapine.
    Srisurapanont M; Suttajit S; Likhitsathian S; Maneeton B; Maneeton N
    Sci Rep; 2021 Apr; 11(1):7583. PubMed ID: 33828206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Samidorphan/olanzapine combination therapy for schizophrenia: Efficacy, tolerance and adverse outcomes of regimen, evidence-based review of clinical trials.
    Rehan ST; Siddiqui AH; Khan Z; Imran L; Syed AA; Tahir MJ; Jassani Z; Singh M; Asghar MS; Ahmed A
    Ann Med Surg (Lond); 2022 Jul; 79():104115. PubMed ID: 35860157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo Characterization of the Opioid Receptor-Binding Profiles of Samidorphan and Naltrexone in Rats: Comparisons at Clinically Relevant Concentrations.
    Tan LA; Gajipara N; Sun L; Bacolod M; Zhou Y; Namchuk M; Cunningham JI
    Neuropsychiatr Dis Treat; 2022; 18():2497-2506. PubMed ID: 36345421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olanzapine/Samidorphan: First Approval.
    Paik J
    Drugs; 2021 Aug; 81(12):1431-1436. PubMed ID: 34304374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of hepatic and renal impairment on the pharmacokinetics of olanzapine and samidorphan given in combination as a bilayer tablet.
    Sun L; Yagoda S; Du Y; von Moltke L
    Drug Des Devel Ther; 2019; 13():2941-2955. PubMed ID: 31686778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioequivalence of Olanzapine Given in Combination With Samidorphan as a Bilayer Tablet (ALKS 3831) Compared With Olanzapine-Alone Tablets: Results From a Randomized, Crossover Relative Bioavailability Study.
    Sun L; McDonnell D; Liu J; von Moltke L
    Clin Pharmacol Drug Dev; 2019 May; 8(4):459-466. PubMed ID: 30059196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olanzapine-samidorphan combination tablets for the treatment of schizophrenia and bipolar I disorder - what is it, and will it be used?
    Faden J; Serdenes R; Citrome L
    Expert Rev Neurother; 2022 May; 22(5):365-376. PubMed ID: 35354374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination Olanzapine and Samidorphan for the Management of Schizophrenia and Bipolar 1 Disorder in Adults: A Narrative Review.
    Haddad HW; Boardman E; Williams B; Mouhaffel R; Kaye AM; Kaye AD
    Health Psychol Res; 2022; 10(3):34224. PubMed ID: 35774916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of the reinforcing potential of samidorphan and naltrexone by fixed and progressive ratio intravenous self-administration testing in heroin-maintained rats.
    Smith SL; Dean RL; Todtenkopf MS; Heal DJ
    J Psychopharmacol; 2019 Mar; 33(3):383-391. PubMed ID: 30676189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.